Erik Harris, Executive Vice President and Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. discusses how the COVID-19 pandemic has impacted the company.
According to Mr. Harris, Ultragenyx has always worked closely with patients and pharmacies to provide treatment as conveniently and safely as possible.
As an example, Mr. Harris discusses how Ultragenyx’s distribution of burosumab-twza (Crysvita) has changed since the rise of COVID-19. Notably, the company proactively reached out to patients being treated with burosumab-twza to assist with continuity of care and petitioned the FDA to make self-administration of the drug an option. This eased many patients’ worries about inviting a nurse into their homes during the pandemic.
For more news about rare disease treatments, visit checkrare.com/treatment/.